Thompson Peter A. 4

What Happened Peter A. Thompson, reported as a 10% owner of Edgewise Therapeutics (EWTX), was granted 16,377 stock options on June 5, 2026. The Form 4 reports the acquisition price as $0.00 (derivative award), resulting in no immediate cash outlay. This is a grant of options (an award), not an open-market purchase or sale.

Key Details

• Transaction date: June 5, 2026; Form filed: June 17, 2026 (filed late relative to the usual 2-business-day Form 4 deadline).
• Grant: 16,377 stock options reported as acquired at $0.00 (derivative).
• Vesting: 100% of the options vest on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholders (per footnote).
• Shares owned after transaction: not specified in the provided filing excerpt.
• No indication of a 10b5-1 plan, cashless exercise, tax withholding, or immediate sale in the filing excerpt.

Context This was an option grant (derivative award) rather than a market purchase — such grants are common for compensation or retention and do not represent an immediate change in public float. Because the filing was submitted about 12 days after the transaction date, disclosure was late, which reduces short-term transparency for investors. As a 10% owner (not necessarily an executive trade), this filing is required under Section 16 rules.